Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 25;83(25):2674-2689.
doi: 10.1016/j.jacc.2024.03.431.

Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review

Affiliations
Free article
Review

Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review

Baljash Cheema et al. J Am Coll Cardiol. .
Free article

Abstract

Iron deficiency and heart failure frequently co-occur, sparking clinical research into the role of iron repletion in this condition over the last 20 years. Although early nonrandomized studies and subsequent moderate-sized randomized controlled trials showed an improvement in symptoms and functional metrics with the use of intravenous iron, 3 recent larger trials powered to detect a difference in hard cardiovascular outcomes failed to meet their primary endpoints. Additionally, there are potential concerns related to side effects from intravenous iron, both in the short and long term. This review discusses the basics of iron biology and regulation, the diagnostic criteria for iron deficiency and the clinical evidence for intravenous iron in heart failure, safety concerns, and alternative therapies. We also make practical suggestions for the management of patients with iron deficiency and heart failure and outline key areas in need of future research.

Keywords: cardiovascular outcomes; clinical trials; heart failure; intravenous iron; iron deficiency; iron repletion.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Cheema has received consulting fees from Caption Health, Inc and Viz.ai; has served on an Advisory Board for Novo Nordisk; and is an advisor with equity interest in Healthspan, Inc and Zoe Biosciences. Dr Ardehali is a consultant for Pharmacosmos. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

MeSH terms

LinkOut - more resources